Credit rating agency, CARE has reaffirmed ‘D’ rating to Themis Medicare’s long term bank facilities worth Rs 13.10 crore and ‘D’ rating to company’s Short term Bank Facilities worth Rs 63.25 crore. Furthermore, the rating agency has also reaffirmed ‘D’ rating to the company’s Long Term Rupee Term Loans worth Rs 27.16 crore. The ratings of Themis Medicare (TML) continue to factor in the delay in debt servicing owing to tight liquidity position.
Themis Medicare is engaged in manufacturing and marketing of active pharmaceutical ingredients (API) and formulations in various therapeutic segments like anti-malarials, pain management, anti-infectives, anesthesia, health and nutrition. The company is also engaged in co-marketing its research-based formulations with other pharmaceutical companies in India and abroad.
